Tirzepatide vs GLP-1 Drugs: Which Reduces Glaucoma Risk? [New Study 2025] (2026)

Bold claim: one GLP-1–based drug, tirzepatide, may lower glaucoma risk more than rivals. But don’t change your prescribing habits yet. Here’s what the newest findings really say, why they matter, and where they fall short.

A large retrospective analysis suggests that tirzepatide (brand names Mounjaro and Zepbound), a dual GIP/GLP-1 medication, is linked to a notably lower risk of glaucoma compared with GLP-1 receptor agonists in people with type 2 diabetes. In matched cohorts exceeding 41,000 patients per group, tirzepatide users showed a reduced risk of primary open-angle glaucoma (risk ratio [RR] 0.50, 95% CI 0.34–0.74). The study also found lower odds of ocular hypertension (RR 0.59, 95% CI 0.40–0.88) and a reduced need for glaucoma treatment (RR 0.54, 95% CI 0.45–0.64).

To put absolute risk into perspective, the glaucoma incidence was about 0.1% in tirzepatide users versus about 0.2% in GLP-1 users. While these numbers are small, the relative reductions are notable and have researchers considering tirzepatide as a potential option for patients with glaucoma risk, or those already diagnosed with glaucoma, where GLP-1–based therapy is appropriate for other conditions.

Why might tirzepatide confer this extra protection? The authors acknowledge that the exact mechanism remains unclear. Hypotheses include improvements in vascular function, reduced metabolic stress on ocular tissues, and better insulin sensitivity. There’s also the possibility that these drugs promote neuroprotective signaling that could help retinal nerve fibers, independent of intraocular pressure.

It’s important to temper excitement with caution. Experts not involved in the study emphasize that tirzepatide should not be viewed as a primary glaucoma treatment. A clinician wouldn’t typically choose a GLP-1–based drug solely to manage glaucoma risk or disease progression; this is not established as a standard glaucoma therapy.

Another related line of evidence comes from earlier work suggesting GLP-1 receptor agonists used for obesity are associated with lower glaucoma risk and reduced ocular hypertension compared with other weight-loss strategies. The current study is distinctive because it directly compares tirzepatide against GLP-1 drugs, rather than comparing different obesity therapies.

Key study details. The analysis used data from 71 U.S. health systems, identifying adults who started tirzepatide or a GLP-1 drug between June 2022 and May 2025, with propensity score matching yielding 41,849 matched pairs. The average participant was about 55 years old; the groups were similar in demographics and comorbidities, including hypertension, hyperlipidemia, chronic kidney disease, and concurrent diabetes medications. Outcomes were defined by new diagnoses of primary open-angle glaucoma or ocular hypertension and initiation of first-line glaucoma treatments.

Subgroup and sensitivity checks showed consistent risk reductions even among participants also taking metformin or insulin, and when comparing tirzepatide to individual GLP-1 drugs like semaglutide and dulaglutide. However, the study relies on administrative codes (ICD-10) and has a relatively short follow-up period, which are notable limitations.

Experts outside the study call for validation through longer-term research with direct eye examinations (for example, intraocular pressure measurements and visual field tests) to confirm the potential protective effect and to understand its durability.

Bottom line for clinicians and patients: the findings are intriguing and may point to a broader ocular benefit of tirzepatide, but they do not establish tirzepatide as a glaucoma treatment. If a patient is already indicated for a GLP-1–based therapy and has glaucoma risk, tirzepatide could be considered as part of the overall treatment plan, but only within current approved indications and with close clinical judgment.

Questions for readers: Do you think these glaucoma-related findings should influence future guidelines or prescribing practices? Could a dual GIP/GLP-1 mechanism offer broader neurovascular protection beyond eye health? Share your thoughts and experiences in the comments.